BTIG Keeps a Buy Rating on Organogenesis Holdings (ORGO)

BTIG analyst Ryan Zimmerman maintained a Buy rating on Organogenesis Holdings (ORGO) yesterday and set a price target of $9.00. The company’s shares closed last Monday at $3.11, close to its 52-week low of $3.00.

According to, Zimmerman is a 5-star analyst with an average return of 10.0% and a 47.0% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Staar Surgical Company, and Zimmer Biomet Holdings.

Currently, the analyst consensus on Organogenesis Holdings is a Strong Buy with an average price target of $8.67, representing a 138.2% upside. In a report released today, Oppenheimer also maintained a Buy rating on the stock with a $9.00 price target.

See today’s analyst top recommended stocks >>

Based on Organogenesis Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $10.74 million. In comparison, last year the company had a GAAP net loss of $9.26 million.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ORGO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Organogenesis Holdings, Inc. is a regenerative medical company. It focuses on the development, manufacture and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company was founded in 1985 and is headquartered in Canton, MA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts